Our goal is to become a fully-integrated biopharmaceutical company and a leader in the discovery, development and commercialization of novel small molecule drugs. Key components of our strategy to achieve our corporate goals are outlined below.
Build and advance our product candidate pipeline. Through our drug discovery and development programs, we have created a broad pipeline of drug candidates spanning a range of therapeutic areas. We plan to continue to aggressively pursue the development and commercialization of these drug candidates. In addition, we believe that the breadth of our capabilities in drug discovery technology will enable us to continue to identify and develop additional drug candidates on an efficient and rapid basis.
Establish strategic alliances with academic institutes and leading pharmaceutical companies. We have established, and expect to continue to build upon, a broad set of strategic alliances with several academic institutes and leading pharmaceutical companies. These collaborations have enabled us to leverage our expertise into additional therapeutic areas, benefit from the therapeutic area expertise and commercial resources of our partners, and augment our financial resources.
Expand our development expertise. From our origins as a drug discovery organization, we have steadily expanded our capabilities in drug development. As we advance our product candidate pipeline, we plan to further augment our development team by adding additional personnel with experience in drug safety, regulatory affairs, statistical methods, project management and medical affairs.
Establish specialized sales and marketing capabilities. We plan to retain China and United States marketing and sales rights or co-promotion rights for our product candidates.